Results 61 to 70 of about 25,820 (298)

Research status of dietary nursing intervention of hyperphosphatemia in hemodialysis patients (血液透析患者高磷血症饮食护理干预的研究现状)

open access: yes中西医结合护理, 2021
Hemodialysis patients are prone to hyperphosphatemia in the process of disease progression, which seriously reduce the patient’s quality of life. In clinical treatment and nursing, dietary nursing intervention can improve the prevention awareness of ...
WANG Liwei (王丽伟)   +4 more
doaj   +1 more source

Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis [PDF]

open access: yes, 2011
Mutations in the GALNT3 gene cause tumoral calcinosis characterized by ectopic calcifications due to persistent hyperphosphatemia. We recently developed Galnt3 knockout mice in a mixed background, which had hyperphosphatemia with increased bone mineral ...
Allen, Matthew R.   +4 more
core   +1 more source

Tumor lysis syndrome [PDF]

open access: yesPediatric Emergency Medicine Journal, 2016
Tumor lysis syndrome (TLS) is an oncologic emergency due to the rapid lysis of tumor cells and subsequent release of large amounts of intracellular potassium, phosphate, and uric acid into the bloodstream.
Hyery Kim
doaj   +1 more source

Mono‐Ethyl‐Phosphonates: Functional Group Masking Strategy to Stabilize and Optimize the Pharmacokinetics of Rare Earth Radiochelates

open access: yesChemistryEurope, EarlyView.
Prodrug strategies are used to enhance the pharmacokinetics of small molecule drugs. Here, this approach to rare earth coordination complexes is adopted with applications as diagnostic and therapeutic radiopharmaceuticals: a mono‐ethyl‐phosphonate polyazamacrocyclic chelator for 44Sc and 177Lu reduces blood and bone uptake.
Jennifer N. Whetter   +8 more
wiley   +1 more source

Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). [PDF]

open access: yes, 2019
Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and ...
Bino, Avi   +2 more
core  

Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study [PDF]

open access: yes, 2015
Seiring dengan menguatnya ideologi nasionalis-sekuler pascakemerdekaan, muncullah konsep nasionalisme berdasarkan sejumlah sumber yang bertolak belakang satu sama lain.
Fumihiko Koiwa, Akira Terao
core   +2 more sources

Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs [PDF]

open access: yesТерапевтический архив, 2016
The review considers the current views of the mechanisms of hyperphosphatemia in patients with chronic renal failure. It shows indications for the use of different classes of phosphate-binding drugs to correct hyperphosphatemia.
Yu S Milovanov   +2 more
doaj  

Development of Deferoxamine‐Functionalized Cyclodextrin Polymer for Targeted Iron Chelation

open access: yesChemistryOpen, EarlyView.
The cyclodextrin polymer is conjugated with 35 deferoxamine units and can form iron(III) complexes. The polymer exhibits significantly lower antiproliferative activity than free deferoxamine. The cyclodextrin polymer with multiple deferoxamine units may present a promising strategy for improving the efficacy of iron chelation therapies.
Roberta Panebianco   +2 more
wiley   +1 more source

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2016
BACKGROUND AND OBJECTIVES People with CKD stages 3-5 and on dialysis (5D) have dramatically increased mortality, which has been associated with hyperphosphatemia in many studies. Oral phosphate binders are commonly prescribed to lower serum phosphate. We
Leena Patel, L. Bernard, G. Elder
semanticscholar   +1 more source

Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Complete resection of the primary tumor is critical for the survival of children with hepatoblastomas (HBs). This prospective clinical study aimed to clarify the outcome of a chemotherapy regimen comprising cisplatin and doxorubicin (PLADO) followed by definitive surgery conducted at the appropriate time in patients with ...
Tomoro Hishiki   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy